Johnson & Johnson's orthopedics sales dip in Q4: 5 notes

Orthopedic

Johnson & Johnson on Jan. 24 posted $23.7 billion in 2022 revenue, a 4.4 percent decrease. Its orthopedic sales remained flat year-over-year, and its fourth-quarter orthopedic sales fell slightly.

Five things to know:

1. Orthopedic sales in the fourth quarter was $2.1 billion, a 0.4 percent decrease. Hip sales rose 1.7 percent year-over-year in the fourth quarter with $385 million, and knee sales grew 3.4 percent with $354 million.

2. Fourth quarter trauma sales fell 2.4 percent year-over-year with $710 million. The spine and sports medicine segments saw $699 million in fourth qarter sales, a 1.3 percent year-over-year decrease. 

3. Full-year orthopedic sales of $8.6 billion was the same compared to 2021 sales. 

4.  MedTech business as a whole brought in $6.8 billion on 2022, a 1.2 percent decrease from 2021.

5. Johnson & Johnson expects 2023 operational revenue to grow 3.5 percent. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers